Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 197 results for low back pain

  1. Minimally invasive sacroiliac joint fusion surgery for chronic sacroiliac pain (HTG436)

    Evidence-based recommendations on minimally invasive sacroiliac joint fusion surgery for chronic sacroiliac pain in adults. This involves fixing the sacrum to the ilium using 2 or 3 metal implants.

  2. Laparoscopic gastric plication for the treatment of severe obesity (HTG293)

    Evidence-based recommendations on laparoscopic gastric plication for the treatment of morbid obesity. This involves folding the stomach in on itself and stitching it together to reduce its volume.

  3. Suspected neurological conditions: recognition and referral (NG127)

    This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.

  4. Differential target multiplexed spinal cord stimulation for chronic lower back and leg pain (MIB305)

    NICE has developed a medtech innovation briefing (MIB) on differential target multiplexed spinal cord stimulation for chronic lower back and leg pain .

  5. Cost saving guidance

    anticipated bed day savings. Capacity savings: £11,600 Guideline on low back pain and sciatica in over 16s: assessment and management...

  6. Percutaneous intradiscal laser ablation in the lumbar spine (HTG230)

    Evidence-based recommendations on percutaneous intradiscal laser ablation in the lumbar spine. This involves using a laser to destroy part of the disc, with the aim of shrinking it.

  7. Neo Pedicle Screw System for spinal fusion surgery (MIB108)

    NICE has developed a medtech innovation briefing (MIB) on the Neo Pedicle Screw System for spinal fusion surgery .

  8. Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain (MIB238)

    NICE has developed a medtech innovation briefing (MIB) on Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain .

  9. What is the clinical and cost effectiveness of opioids for the management of acute sciatica?

    did not improve sciatica symptoms, and oral corticosteroids did not improve pain or function, but may have an impact on quality of life....

  10. What is the clinical and cost effectiveness of antidepressants for the management of sciatica?

    did not improve sciatica symptoms, and oral corticosteroids did not improve pain or function, but may have an impact on quality of life....

  11. What is the clinical and cost effectiveness of opioids for the management of acute sciatica?

    applicable) Source guidance details Comes from guidance Low back pain and sciatica in over 16s: assessment and management Number

  12. Cerebral palsy in under 25s: assessment and management (NG62)

    This guideline covers diagnosing, assessing and managing cerebral palsy in children and young people from birth up to their 25th birthday. It aims to make sure they get the care and treatment they need for the developmental and clinical comorbidities associated with cerebral palsy, so that they can be as active and independent as possible.

  13. Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain (HTG498)

    Evidence-based recommendations on the Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain.

  14. Community pharmacies: promoting health and wellbeing (NG102)

    This guideline covers how community pharmacies can help maintain and improve people’s physical and mental health and wellbeing, including people with a long-term condition. It aims to encourage more people to use community pharmacies by integrating them within existing health and care pathways and ensuring they offer standard services and a consistent approach. It requires a collaborative approach from individual pharmacies and their representatives, local authorities and other commissioners.